Cognition in older adults with myeloma undergoing CAR-T therapy
Categories (click each to see list of all clinical trials associated with that category): Myeloma/Plasma Cell Dyscrasia (ONC)
Current Status: Open
Phase: N/A (Cancer Control)
Principal Investigator: Wildes, Tanya
Contact Information:
Kellee Halliburton
khalliburton@unmc.edu
Summary
1.1. Primary Objective:
1.1.1. To estimate the proportion of individuals who complete both baseline and 3-month neuropsychological testing to establish the feasibility of completing longitudinal comprehensive neuropsychological testing in older adults with myeloma undergoing CAR-T
1.2. Secondary Objectives:
1.2.1. To estimate the prevalence of cognitive impairment in older adults prior to CAR-T therapy
1.2.2. To estimate the incidence of clinically important change in subjective cognitive function over 3 months of follow-up
1.2.3. To estimate the change in neurocognitive function composite score over 3 months of follow-up
1.2.4. To estimate the change in individual cognitive domains over 3 months of follow-up
1.3. Exploratory Objectives:
1.3.1. To estimate the concordance between the baseline International Myeloma Working Group Frailty score using self-reported Charlson Comorbidity Index and the standard Charlson Comorbidity Index
1.3.2. To explore the association between the severity of immune effector cell-associated neurotoxicity syndrome (ICANS) and change in neurocognitive outcomes over 3 months of follow-up